PA5-42058

antibody from Invitrogen Antibodies

Targeting: HSD17B1 EDH17B2, EDHB17, HSD17, MGC138140, SDR28C1

Antibody data

Submit

Validation data

Product number: PA5-42058 - Provider product page
Provider: Invitrogen Antibodies
Product name: HSD17B1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: Peptide sequence: MARTVVLITG CSSGIGLHLA VRLASDPSQS FKVYATLRDL KTQGRLWEAA Sequence homology: Cow: 100%; Dog: 100%; Guinea Pig: 91%; Horse: 100%; Human: 100%; Mouse: 100%; Pig: 100%; Rabbit: 100%; Rat: 100%
Reactivity: Human, Mouse
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.5 mg/mL
Storage: -20° C, Avoid Freeze/Thaw Cycles

HSD17B1 protein structure - PA5-42058 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Treatment of HESCs with activated platelets resulted in increased production of E 2 through upregulation of steroidogenic genes. ( A ) Concentrations of E 2 in the supernatant of HESCs (n = 7) and ESCL (n = 5) treated with PBS, platelets, activated platelets, and thrombin alone. Gene ( B ) and protein ( D ) expression levels of the genes involved in estrogen biosynthesis: StAR, CYP11A1, HSD3B2, CYP17A1, CYP19A1 and HSD17B1 in HESCs co-cultured with PBS, platelets, activated platelets and thrombin alone. ( C ) Representative Western blotting results for StAR, HSD3B2, aromatase and HSD17B1. Fold change for SF-1 ( E ) and p-CREB ( F ) protein expression in HESCs co-cultured with PBS, activated platelets and thrombin alone. ""*"" denotes that the p-value of the difference between the designated treatment and the PBS treatment is less than 0.05. Abbreviations used: PLT: platelets; A.PLT: activated platelets; THMB: thrombin. Paired Wilcoxon's test was used.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 3 Effect of suppression of NF-kappaB activation by JSH-23 on the production of E 2 and expression of steroidogenic genes in HESCs. ( A ) Concentrations of E 2 in the supernatant of HESCs (n = 8) treated with vehicle, activated platelets and activated platelets + JSH-23. ( B ) Gene expression levels of the genes involved in estrogen biosynthesis StAR, HSD3B2, CYP19A1 and HSD17B1 in HESCs co-cultured with vehicle, activated platelets and activated platelets + JSH-23. ( C ) Representative Western blotting results for StAR, HSD3B2, aromatase and HSD17B1 protein expression. ( D ) Summary of fold changes of protein expression levels of StAR, HSD3B2, aromatase and HSD17B1 in HESCs (n = 8) treated with vehicle, activated platelets and activated platelets + JSH-23. Summary of fold changes for SF-1 ( E ) and p-CREB ( F ) protein expression in HESCs (n = 8) treated with vehicle, activated platelets and activated platelets + JSH-23. ""*"" denotes that the p-value of the difference between the groups is less than 0.05. NS: p > 0.05. Paired Wilcoxon's test was used.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 Effects of neutralization of TGF-beta1 by A83-01 on the production of E 2 and expression of genes involved in steroidogenesis in HESCs. ( A ) Concentrations of E 2 in the supernatant of HESCs (n = 8) treated with vehicle, activated platelets and activated platelets + A83-01. ( B ) Gene expression levels of StAR, HSD3B2, CYP19A1 and HSD17B1 in HESCs (n = 8) treated with vehicle, activated platelets and activated platelets + A83-01. ( C ) Representative Western blotting results for StAR, HSD3B2, aromatase and HSD17B1 in HESCs under different treatments. ( D ) Summary of fold changes of protein expression levels of StAR, HSD3B2, aromatase and HSD17B1 in HESCs (n = 8) treated with vehicle, activated platelets and activated platelets + A83-01. Western blot analysis results for SF-1 ( E ) and p-CREB ( F ) proteins in HESCs treated with vehicle, activated platelets and activated platelets + A83-01. ""*"" denotes that the p-value of the difference between the groups is less than 0.05. NS: p > 0.05. Paired Wilcoxon's test was used.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Effect of non-immune serum (NI), platelet infusion (PI) and platelet depletion (PD) on lesional development and lesional expression of steroidogenic proteins in mice with induced endometriosis. ( A ) Change in hotplate latency for mice in the NI, PD and PI groups tested at the time indicated. ( B ) Total lesion weight for mice in the 3 treatment groups. Boxplots of lesional staining levels in NI, PD and PI groups: StAR ( C ), HSD3B2 ( D ), aromatase ( E ), HSD17B1 ( F ), SF-1 ( G ), and p-CREB ( H ). The dotted horizontal line represents the median of all 3 groups. Symbols of statistical significance: *: p < 0.05, **:p < 0.01, ***: p < 0.001. n = 10 for each group. Except in ( A ), where the comparison was made using Kruskal's test, all tests were made using Wilcoxon's test in comparison with the NI group. ( I ) Representative photomicrographs of StAR, HSD3B2, aromatase, HSD17B1, SF-1 and p-CREB staining in endometriotic lesions (x400) in Balb/c mice with induced endometriosis in different treatment groups. Scale bar = 50 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 7 Effect of antagonism of TGF-beta1 (by SB431542) or of NF-kappaB (by JSH-23) on lesional development and lesional expression of steroidogenic proteins in mice with induced endometriosis. ( A ) Change in hotplate latency for mice treatment with vehicle (untreated, or U), antagonism of TGF-beta1 (T), and antagonism of NF-kappaB (N) tested at the time indicated. ( B ) Total lesion weight in the 3 groups of mice. ( C ) Boxplots of the extent of lesional platelet aggregation using CD41 the 3 groups of mice. Boxplots of lesional staining levels in the 3 groups of mice: StAR ( D ), HSD3B2 ( E ), aromatase ( F ), HSD17B1 ( G ), SF-1 ( H ), and p-CREB ( I ). The dotted horizontal line represents the median of all 3 groups. Symbols of statistical significance: *: p < 0.05, **: p < 0.01, ***: p < 0.001. NS: p > 0.05. n = 10 for each group. Except in ( A ), where the comparison was made using Kruskal's test, all tests were made using Wilcoxon's test in comparison with the untreated group ( U ). ( J ) Representative immunoreactivity staining of CD41, StAR, HSD3B2, aromatase, HSD17B1, SF-1 and p-CREB in the endometriotic lesions (x400) in Balb/c mice with induced endometriosis which then treatment with vehicle, SB431542 (an antagonist for TGF-beta1) and JSH-23 (an antagonist for NF-kappaB) for two weeks. Scale bar = 50 mum.